Abbott Laboratories agreed to acquire Exact Sciences for $23 billion, a move that immediately expands Abbott’s diagnostics footprint into oncology screening, therapy selection and minimal residual disease testing. Abbott said the deal will be accretive to margins and broaden its addressable market by adding products including Cologuard and Oncotype Dx. Executives framed the acquisition as strategic entry into multibillion‑dollar cancer diagnostics segments—screening, therapy selection and recurrence monitoring—with near‑term revenue upside and longer‑term pipeline opportunities. The transaction is set to close in 2026 and signals potential further consolidation in the central‑lab and precision oncology testing space.